BioPharm Editor in Chief, Laura Bush, Joins Interphex Conference Advisory Board
Laura Bush, editor in chief of BioPharm International, has joined the 2010 Interphex Conference Advisory Board.
Laura Bush, editor in chief of BioPharm International, has joined the 2010 Interphex Conference Advisory Board.
The board consists of pharmaceutical and biopharmaceutical manufacturers, suppliers, and industry experts. Board members are asked to represent the needs of the industry at large, and to recommend speakers as able.
BioPharm International has been a media partner at Interphex New York for the past several years. At Interphex 2009, BioPharm sponsored the keynote panel discussion, which was chaired by Laura Bush and featured several notable industry experts, including G. Steven Burrill, Tim Moore of Genentech, Divakar Ramakrishnan of Eli Lilly, and Michael D. Kowolenko of Wyeth.
Podcasts with speakers Tim Moore and Michael Kowolenko can be found at www.biopharminternational.com/InterphexKeynote.
A vidcast of the keynote can be found on the Interphex365 web site.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
